These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1662 related articles for article (PubMed ID: 17708140)

  • 21. Cytochrome p450 part 3: drug interactions: essential concepts and considerations.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):697-706. PubMed ID: 24295196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-associated disease: cytochrome P450 interactions.
    Mann HJ
    Crit Care Clin; 2006 Apr; 22(2):329-45, vii. PubMed ID: 16678003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
    Masubuchi Y; Horie T
    Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
    Tang C; Lin JH; Lu AY
    Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism.
    Shephard EA; Phillips IR
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1083-94. PubMed ID: 20629583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug metabolism by cytochromes P450 in the liver and small bowel.
    Watkins PB
    Gastroenterol Clin North Am; 1992 Sep; 21(3):511-26. PubMed ID: 1516957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S; Sinal CJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinatorial pharmacogenetics.
    Wilke RA; Reif DM; Moore JH
    Nat Rev Drug Discov; 2005 Nov; 4(11):911-8. PubMed ID: 16264434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 84.